Creating new antimicrobial drugs will require governments working with industry
09 April 2019
The pharmaceutical industry has demonstrated its willingness to take on the risk and uncertainty that come with trying to develop medicines that address unmet needs. When it comes to antimicrobial drugs, the hurdle is not that the risks are too high, it is that the rewards are too low. The big question is this: What is society as whole ready to invest to avoid a post-antibiotic era?
Further reading: STAT News
Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
